3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 3
2
Phase NA
1
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
3
Waldenstrom Macroglobulinemia
1
Stomach Neoplasms
1
Recurrence
1
Neoplasms, Second Primary
1
Neoplasms
1
NSCLC
1
Lymphoma, Mantle-Cell
1
Immunoglobulin Light-chain Amyloidosis
1
Interventions
Brentuximab Vedotin
3
relmacabtagene autoleucel
2
fludarabine phosphate
2
fludarabine
2
Cytarabine
2
Bortezomib
2
Antilymphocyte Serum
2
xihuang
1
tocilizumab
1
tislelizumab
1
sofosbuvir-velpatasvir drug combination
1
sintilimab
1
rasburicase
1
ledipasvir
1
entecavir
1
apatinib
1
aflibercept
1
acalabrutinib
1
Urate Oxidase
1
Trabectedin
1
Thiotepa
1
Thalidomide
1
Tenofovir
1
Tamsulosin
1
Sofosbuvir
1
Sevoflurane
1
Rivaroxaban
1
Ribavirin
1
Radiotherapy
1
Radiosurgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Recurrence
×
Thalidomide
×
Clear all
NCT00652041
2011-09-19
TaCyDexVMP7
PETHEMA Foundation
Phase 4
Completed
40 enrolled